Stevanato Group (NYSE:STVN) Stock: Insider Donald Morel, Jr. Buys 25,000 Shares

Posted by Brian Himes on Nov 12th, 2026

Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) Director Donald Morel, Jr. purchased 25,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were purchased at an average price of €13.07 per share, for a total transaction of €326,750.00. Following the purchase, the director directly owned 62,424 shares in the company, valued at €815,881.68. The trade was a 66.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stevanato Group Trading Down 0.2%

STVN opened at €13.88 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.73 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 1.40 and a beta of 0.80. The business’s 50 day moving average is €19.36 and its two-hundred day moving average is €17.93. Stevanato Group S.p.A. has a 52 week low of €12.05 and a 52 week high of €24.51.

Stevanato Group (NYSE:STVN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01). Stevanato Group had a net margin of 11.24% and a return on equity of 10.51%. The business had revenue of €326.06 million during the quarter. On average, research analysts predict that Stevanato Group S.p.A. will post 0.67 EPS for the current year.

Institutional Investors Weigh In On Stevanato Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC raised its holdings in Stevanato Group by 131.2% during the second quarter. Squarepoint Ops LLC now owns 193,311 shares of the company’s stock worth $3,493,000 after purchasing an additional 109,702 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Stevanato Group during the second quarter worth $22,621,000. Fenimore Asset Management Inc acquired a new stake in Stevanato Group in the third quarter valued at $12,212,000. Confluence Investment Management LLC acquired a new stake in Stevanato Group in the second quarter valued at $6,062,000. Finally, Royal Bank of Canada grew its holdings in Stevanato Group by 15.8% in the first quarter. Royal Bank of Canada now owns 421,696 shares of the company’s stock valued at $5,798,000 after purchasing an additional 57,536 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently commented on STVN. Citigroup reduced their target price on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Deutsche Bank assumed coverage on Stevanato Group in a research report on Wednesday, October 7th. They issued a “hold” rating for the company. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 4th. UBS Group decreased their target price on shares of Stevanato Group from $23.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 4th. Finally, Weiss Ratings raised shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy”.

View Our Latest Stock Report on STVN

Stevanato Group Company Profile

(Get Free Report)

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.